Apomorphine
Apomorphine is a dopamine agonist medication used primarily to manage episodes of sudden, intermittent worsening of motor symptoms, known as “OFF” episodes, in patients with advanced Parkinson’s disease. It works by stimulating dopamine receptors in the brain, helping improve movement and reduce symptoms such as muscle stiffness, tremor, and difficulty initiating movement. Depending on the formulation and country-specific approval, apomorphine may be administered by subcutaneous injection or continuous subcutaneous infusion, while certain oral or sublingual formulations have been used for other indications in some markets. Common adverse effects include nausea, vomiting, dizziness, drowsiness, and injection-site reactions. Important risks include low blood pressure, fainting, hallucinations, impulse-control disorders, and QT-interval prolongation. Treatment should be initiated and monitored by a specialist, with appropriate management of nausea and careful assessment of cardiovascular status and potential drug interactions.
Apomorphine was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Apomorphine, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Apomorphine from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Apomorphine, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
